Published in Ther Adv Neurol Disord on September 01, 2012
Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol (2013) 1.16
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract (2015) 0.88
Cannabinoids for pediatric epilepsy? Up in smoke or real science? Transl Pediatr (2015) 0.76
Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report. Ther Adv Neurol Disord (2013) 0.76
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord (2016) 0.75
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 4.27
Cannabis use and risk of lung cancer: a case-control study. Eur Respir J (2008) 3.29
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry (2009) 2.24
Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol (1990) 2.18
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005) 1.97
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93
Adverse effects of medical cannabinoids: a systematic review. CMAJ (2008) 1.86
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler (2006) 1.80
CB2 receptors in the brain: role in central immune function. Br J Pharmacol (2007) 1.66
A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses (2005) 1.55
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol (2007) 1.48
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs (2010) 1.34
Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004. Eur J Neurol (2004) 1.28
Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology (2009) 1.20
Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res (2011) 1.18
Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther (2010) 1.08
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf (2011) 1.05
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol (2007) 1.05
Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.03
Symptomatic management in multiple sclerosis. Neurol Clin (2011) 1.03
Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs (2010) 0.98
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler (2011) 0.97
The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther (2010) 0.96
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord (2011) 0.94
The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol (2010) 0.93
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler (2010) 0.93
A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology (1994) 0.92
Stop using the Ashworth scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry (2010) 0.91
Neuroprotective agents: cannabinoids. Clin Immunol (2011) 0.90
Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci (2009) 0.89
Multiple sclerosis, cannabinoids, and cognition. J Neuropsychiatry Clin Neurosci (2008) 0.81
Cannabis-based medicines in multiple sclerosis--a review of clinical studies. Immunobiology (2010) 0.81
Cannabinoids and experimental models of multiple sclerosis. Immunobiology (2009) 0.81
Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry (2009) 0.81
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. Expert Rev Neurother (2007) 0.79
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Guillain-Barré syndrome. N Engl J Med (2012) 6.28
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol (2010) 3.26
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet (2003) 3.22
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis (2010) 2.32
New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci (2002) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood (2008) 2.01
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol (2012) 1.84
Chronic inflammatory demyelinating polyneuropathy. N Engl J Med (2005) 1.79
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci (2003) 1.65
Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry (2013) 1.63
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology (2013) 1.56
Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol (2006) 1.54
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol (2003) 1.48
Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation (2012) 1.47
Towards individualised multiple-sclerosis therapy. Lancet Neurol (2005) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Exp Neurol (2008) 1.44
Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs (2014) 1.44
Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol (2009) 1.42
Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol (2009) 1.42
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother (2012) 1.40
Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol (2005) 1.40
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol (2010) 1.36
Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol (2007) 1.34
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler (2013) 1.30
Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol (2009) 1.28
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol (2005) 1.25
Enhancing remyelination in disease--can we wrap it up? Brain (2011) 1.25
Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs (2008) 1.25
Optical coherence tomography in parkinsonian syndromes. PLoS One (2012) 1.24
In vivo MRI of brain inflammation in human ischaemic stroke. Brain (2004) 1.24
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol (2009) 1.24
Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors. Ann Neurol (2009) 1.24
Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol (2005) 1.23
Animal models of multiple sclerosis--potentials and limitations. Prog Neurobiol (2010) 1.23
Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review. Arch Neurol (2003) 1.22
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
The complex world of oligodendroglial differentiation inhibitors. Ann Neurol (2011) 1.19
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol (2006) 1.17
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol (2009) 1.15
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol (2007) 1.14
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol (2005) 1.13
Remyelinating strategies for the treatment of multiple sclerosis. Prog Neurobiol (2002) 1.12
Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2009) 1.12
Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain (2003) 1.12
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol (2005) 1.10
The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J Cell Biol (2005) 1.10
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09